GO Capital Fund

LeddarTech provides the most flexible, robust and accurate sensing technology for advanced driver assistance systems (ADAS) and autonomous driving (AD). Our solutions enable customers to solve critical environmental sensing, fusion and perception challenges across the entire value chain. The company develops cost-effective perception solutions scalable from Level 2 ADAS to Level 5 full autonomy with LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types (camera, radar and LiDAR) and configurations. LeddarTech’s disruptive technology reduces risks, accelerates development cycles and enables faster time-to-market. We are responsible for several cutting-edge remote-sensing innovations, with over 140 patents granted or applied for that enhance ADAS and autonomous driving capabilities. Our customers are OEMs and Tier 1-2 automotive suppliers looking for sensing and perception solutions that allow them to meet their key performance, cost and development time requirements for faster time-to-market and ROI.

WhatsNexx Moments leverages the world’s leading marketing applications, consolidating campaign management across channels and locations to build intuitive and delightful customer experiences. Our suite and solutions empower marketers to collect and integrate raw customer data into profiles and segments, to design and manage sophisticated, automated campaigns, and to visualize and optimize the customer journey in real-time - all using the tools and apps you already trust to deliver the front line experiences.

LeddarTech provides the most flexible, robust and accurate sensing technology for advanced driver assistance systems (ADAS) and autonomous driving (AD). Our solutions enable customers to solve critical environmental sensing, fusion and perception challenges across the entire value chain. The company develops cost-effective perception solutions scalable from Level 2 ADAS to Level 5 full autonomy with LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types (camera, radar and LiDAR) and configurations. LeddarTech’s disruptive technology reduces risks, accelerates development cycles and enables faster time-to-market. We are responsible for several cutting-edge remote-sensing innovations, with over 140 patents granted or applied for that enhance ADAS and autonomous driving capabilities. Our customers are OEMs and Tier 1-2 automotive suppliers looking for sensing and perception solutions that allow them to meet their key performance, cost and development time requirements for faster time-to-market and ROI.

Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.

Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

WhatsNexx Moments leverages the world’s leading marketing applications, consolidating campaign management across channels and locations to build intuitive and delightful customer experiences. Our suite and solutions empower marketers to collect and integrate raw customer data into profiles and segments, to design and manage sophisticated, automated campaigns, and to visualize and optimize the customer journey in real-time - all using the tools and apps you already trust to deliver the front line experiences.

Neuralitic Systems' helps mobile service operators understand the mobile data user behaviours that influence data service adoption, so that they can automatically uncover new trends and habits and dynamically leverage these emerging behaviours to ignite data revenue growth.

Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.

Leap Medical, Inc. engages in designing, developing, manufacturing, and marketing products that provide the earliest possible indicators of a patient's medical condition. The company is based in Montreal, Canada.

Neuralitic Systems' helps mobile service operators understand the mobile data user behaviours that influence data service adoption, so that they can automatically uncover new trends and habits and dynamically leverage these emerging behaviours to ignite data revenue growth.

Allostera Pharma is a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes.

Neuralitic Systems' helps mobile service operators understand the mobile data user behaviours that influence data service adoption, so that they can automatically uncover new trends and habits and dynamically leverage these emerging behaviours to ignite data revenue growth.

Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.